Rockwell Medical, Inc. has announced that it will present data on the Pharmacokinetics of Triferic Administered IV and via HD at the Renal Research Institute 19th International Conference at Caesar's Palace in Las Vegas. Triferic is the only FDA approved therapy indicated to replace iron replacement and maintain hemoglobin in chronic kidney disease patients receiving dialysis.